← All trials
NCT03808935
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2019
- Primary completion
- Jan 10, 2021
- Completion date
- Jan 10, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ontario Brain InstituteLead sponsor
- University of TorontoCollaborator
- University of TorontoOverall official - principal investigator
- University of Western OntarioCollaborator
- University of Western OntarioOverall official - principal investigator
- MedReleafCollaborator
- Ontario Brain InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.